My goal with this marketplace service is to create a home for biotech investors alike. Whether you are a seasoned biotech investor or you are new to the space I went everyone to feel as if they are at home. There is no right or wrong with respect to opinions and ideas.
What Will You Achieve With A Subscription Here?
My goal is to educate people on my model 10 portfolio of small-cap biotech stocks with deep full analysis research. I will get into a deeper analysis as opposed to what other authors offer on other sites. You get news from those sites, but what differentiates this service is that you get a full understanding of the biotech in question. I will first focus on 10 small-cap biotech stocks that I like, but it won't end there. My service will always be evolving, and I would like to add research of other biotech stocks that have positive news. In addition, I will be updating my first 10 model portfolio on a regular basis as well. Subscribers can expect at a minimum between 2 to 3 articles per week. The reason for doing this many is that so I can accomplish two items. For one, biotech investing is deep and I want to create articles that have depth to them. I want you to not only understand the biotech itself, but I also want everyone on my marketplace to learn about biotech investing. When subscribing to my platform you will see that you will become a better biotech investor.
Deep Dive Analysis
When investing in the biotech sector there are multiple aspects at play. They involve learning the science of what you are investing in, the pipeline, the drug, the trials, catalysts, dilution, potential risks, and several other aspects. When you read other sites you notice that they just lay out the news. Well, guess what? Just reading news on a biotech stock does not make one a better biotech investor. That's where my service comes in, I take a full on approach to a biotech. I discuss its science whether it is good to invest in or not. Does it have an adequate pipeline? Are the clinical trials set up properly? Does data to date imply that the biotech in question is a good investment opportunity or a major trap? These are the types of questions I will be doing a deep analysis on. In addition, in the articles I write I will recommend whether or not you should buy, sell, or hold a particular biotech stock. You will get actual actionable analysis from me.
What I find most fascinating about the biotech sector is the open community of investors coming together to find the right biotech stock to invest in. My goal here is to create a community of like minded biotech investors where we can chat and discuss biotech stocks in detail. What does this accomplish? Not only do you learn about biotech investing from me, but you get some advice from your peers. The biotech/pharma sector is all about learning new things everyday. I have been investing and writing about biotech for many years now. One thing that I have picked up in this sector is that you are always learning something new. Whether it is about a disease, technology, clinical trial setup, etc you are always finding new things to research about.
It all boils down to what type of credentials do I have to be talking about biotech stocks. Why should subscribers listen to me? That's because I have learned many things in this sector over the years. For starters, I have a huge following on stocktwits.com under my profile name BioPharmaPro (57,684 followers at the time of this writing). I have relayed ideas and have helped many traders and investors on there to learn about biotech investing. I earned that many followers on that platform for a reason. The next item I will talk about will be my Seeking Alpha profile. With only 123 total Seeking Alpha articles I have written under my name Terry Chrisomalis (current amount of Seeking Alpha articles at time of writing), I'm ranked #2 in healthcare on the leader board. That's not all my credentials that I have. In addition, I have written a host of articles on another platform known as Talkmarkets.com, with my profile name as Terry Chrisomalis. There you can read my other biotech articles I have written about over the years.
Learning Is Key
With a subscription here, I want everyone to learn everything there is about the biotech/pharma sector. If you have a question or need to understand something in detail don't hesitate to ask me. I will try to get back to you as fast as possible. I will do my best to answer everyone that needs assistance with this space. Trust me, despite all the due diligence done in this space it is not easy to achieve success. Drug trials are still a gamble no matter how much research and time you have put in. That's why one must have a backup plan just in case things go south. With my subscription you will learn about being a more conservative investor. I will tell you right now, there is no hype. I analyze and relay everything. Despite the belief that a biotech stock looks promising, I will not hesitate to relay the risks. If my subscribes learn anything from my marketplace it will be that you never invest in the biotech sector with 100% certainty. There is always the risk of failure, and that's something that I can't stress enough.
The promotional Price for Biotech Analysis Central is $49 per month or $399 per year at a 33.50% discount. As always there will be a 2-week free trial period to see if Biotech Analysis Central is right for you. We hope that you are willing to take the steps necessary to learn how to invest in the biotech sector. Since the inception of Biotech Analysis Central there have been a lot of good picks, but most notably is Sangamo Therapeutics (SGMO) which is currently up by 86.51% to $23.50 per share, (as of this update) since I gave my recommendation on it for my Model 10+ Portfolio when it traded at $12.60 per share back on October 25, 2017. I recommended Immunomedics (IMMU) back on October 14, 2017 in the Model 10+ Portfolio at $11.72 per share and today it trades at around $15.62 per share (up 33.28% as of update since my recommendation on it). For more picks like these, and incredible biotech research don't hesitate to try a 2-week free trial today. If for whatever reason you are not satisfied with the service after 2-weeks you can cancel without being charged a dime. I hope you take the time to consider trying the service today.
Terry Chrisomalis of Biotech Analysis Central.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical investment research service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to my Service, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers deep dive analysis of many pharmaceutical companies throughout the biotech sector. Come see for yourself if my service is right for you.
New Promotion Pricing: The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.
Author's note: To get these types of premium articles on attractive biotech and pharma stocks as soon as they are published, just click here for my profile. Hit the big orange "Follow" button and choose the real-time alerts option thank you for taking the time to read my analysis.